All News

Here is a basic guide to what you need to know about stage 2 papillary thyroid cancer.

What are we supposed to do to be a “true” friend to someone who is facing cancer?

The Food and Drug Administration granted fast track designation to HDP-101 for the treatment of multiple myeloma.

The MELODY study found music therapy to be effective at relieving the anxiety of cancer survivors.

Denial is a very powerful thing, but it is one that can have serious negative consequences.

After being diagnosed with stage 3 triple-negative breast cancer at 29, Meagan Pettit urges young adults to seek community and define life beyond diagnosis.

Fran Curtis is a survivor of breast, appendix and skin cancer, but said bladder cancer was the toughest.

The story of prevention doesn't end with a surgery date or a clean scan — it unfolds over decades, shaped by habits, choices and vigilance.

In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.

Experts discuss how better hospice and home care reimbursement can help patients receive compassionate end-of-life care at home.

Get the facts on stage 1 multiple myeloma, including why your doctor may recommend active surveillance and what the latest treatment options are.

The addition of postsurgical Verzenio to endocrine therapy provided a benefit in HR–positive, HER2-negative breast cancer.

Learn what stage 2 ovarian cancer means, how it’s diagnosed, treatment options like surgery and chemotherapy, and key questions to ask your oncologist.

Shopping for prostheses reminded me of being in a very popular old toy store.

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T cell therapy is changing treatment decisions.

In PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma buparlisib and paclitaxel was not associated with a survival improvement.

In patients with operable, newly diagnosed brain metastases, GammaTile was associated with reduction in the risk of tumor recurrence or death.

Breast cancer survivors highlighted guidance and encouragement they received when first diagnosed, offering reassurance for those who are newly diagnosed.

VCN-01 plus standard chemotherapy and Abraxane proved safe and effective for patients with metastatic pancreatic cancer.

Camrelizumab plus famitinib extended progression-free survival to 11.1 months versus 7.5 months with chemotherapy in recurrent or metastatic cervical cancer.

Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

Trodelvy plus Keytruda may maintain quality of life and slow physical decline in metastatic triple-negative breast cancer.

Antibody-drug conjugate treatment rates increased 3.7-fold from 2021 to 2023 for patients with metastatic breast cancer.

The cancer vaccine IO102-IO103 plus Keytruda was associated with a clinically relevant improvement in median progression-free survival.

Enhertu plus Perjeta improved progression-free survival versus THP in patients with HER2-positive advanced or metastatic breast cancer across subgroups.

After her follicular lymphoma diagnosis, Karen Cohn reflects on how cancer reshaped her view of mortality and her choice to keep living fully.

Ivonescimab plus chemotherapy significantly improved progression-free survival versus Tevimbra advanced squamous non–small cell lung cancer.

Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.